Novasep is reporting the opening of a new 2,000 square meter facility in Shanghai’s Pudong district. The site is expected to boost Novasep's process development and engineering capabilities to cater to Chinese and East Asian demand.
Novasep launched its previous facilities in Shanghai in 2006 and says that it quickly outgrew the site as it doubled its staff to almost 50 between 2010 and 2012. The expanded site now includes 800 m2 dedicated to innovation and process development through new laboratory, piloting, and FAT testing areas.
Novasep has seen continued growth in demand in East Asia for its design and supply of purification technologies and integrated processes in batch and continuous membrane filtration, ion exchange, and chromatography. Novasep is also facing increasingly challenging purification requests, driven by the need for life science industries to reach maximum throughput with low capital and production costs as well as minimum environmental impact.
The increased innovation capabilities at the Shanghai site will allow Novasep to meet this demand and advance on the 50 purification processes already developed by Novasep in Shanghai. By increasing engineering capabilities, Novasep will expand output for its turnkey purification process solutions for its key markets of biologic drugs, pharmaceuticals, and industrial biotech.
Novasep is a global provider of solutions to produce active molecules at the required purity. Its offerings include process development services, purification equipment and turnkey processes, contract manufacturing services, and complex active molecules to serve pharmaceutical, biopharmaceutical, agrochemical, fine chemical, food and functional ingredients, as well as white biotechnology industries. Besides Shanghai the company has 12 global synthesis and process sites in France, U.S., Germany, Belgium, and the Bahamas.